Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of ...
Agreement Reached on Primary Endpoint and Phase 3 Trial DesignOral APX3330 is a Late-Stage Clinical Asset Available for PartneringFARMINGTON ...
Endo Launches ADRENALIN® Ready-to-Use Premixed Bag, the First and Only FDA-Approved ...
MALVERN, Pa. , Dec. 2, 2024 /CNW/ -- Endo, Inc. (OTCQX: NDOI ) announced today the launch of its ADRENALIN ® (epinephrine in 0.9% sodium chloride injection) ready-to-use premixed bag, the first and ...